186 related articles for article (PubMed ID: 31766274)
1. Characterising Mutational Spectra of Carcinogens in the Tumour Suppressor Gene
Hölzl-Armstrong L; Kucab JE; Korenjak M; Luijten M; Phillips DH; Zavadil J; Arlt VM
Methods Protoc; 2019 Nov; 2(4):. PubMed ID: 31766274
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Kucab JE; van Steeg H; Luijten M; Schmeiser HH; White PA; Phillips DH; Arlt VM
Mutat Res; 2015 Mar; 773():48-62. PubMed ID: 25847421
[TBL] [Abstract][Full Text] [Related]
3. Nutlin-3a selects for cells harbouring TP53 mutations.
Kucab JE; Hollstein M; Arlt VM; Phillips DH
Int J Cancer; 2017 Feb; 140(4):877-887. PubMed ID: 27813088
[TBL] [Abstract][Full Text] [Related]
4. Mutagenicity of acrylamide and glycidamide in human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Hölzl-Armstrong L; Kucab JE; Moody S; Zwart EP; Loutkotová L; Duffy V; Luijten M; Gamboa da Costa G; Stratton MR; Phillips DH; Arlt VM
Arch Toxicol; 2020 Dec; 94(12):4173-4196. PubMed ID: 32886187
[TBL] [Abstract][Full Text] [Related]
5. Mutagenicity of N-hydroxy-4-aminobiphenyl in human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Hölzl-Armstrong L; Kucab JE; Zwart EP; Luijten M; Phillips DH; Arlt VM
Environ Mol Mutagen; 2021 Apr; 62(4):252-264. PubMed ID: 33620775
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activation of diesel exhaust carcinogens in primary and immortalized human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Kucab JE; Phillips DH; Arlt VM
Environ Mol Mutagen; 2012 Apr; 53(3):207-17. PubMed ID: 22351035
[TBL] [Abstract][Full Text] [Related]
7. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model.
Kucab JE; Phillips DH; Arlt VM
FEBS J; 2010 Jun; 277(12):2567-83. PubMed ID: 20553493
[TBL] [Abstract][Full Text] [Related]
8. TP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human TP53 knock-in mouse embryo fibroblasts.
Kucab JE; Zwart EP; van Steeg H; Luijten M; Schmeiser HH; Phillips DH; Arlt VM
DNA Repair (Amst); 2016 Mar; 39():21-33. PubMed ID: 26723900
[TBL] [Abstract][Full Text] [Related]
9. Mutagenicity of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Hölzl-Armstrong L; Moody S; Kucab JE; Zwart EP; Bellamri M; Luijten M; Turesky RJ; Stratton MR; Arlt VM; Phillips DH
Food Chem Toxicol; 2021 Jan; 147():111855. PubMed ID: 33189884
[TBL] [Abstract][Full Text] [Related]
10. Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing.
Besaratinia A; Pfeifer GP
FASEB J; 2010 Aug; 24(8):2612-9. PubMed ID: 20371617
[TBL] [Abstract][Full Text] [Related]
11. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
12. The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences.
vom Brocke J; Krais A; Whibley C; Hollstein MC; Schmeiser HH
Mutagenesis; 2009 Jan; 24(1):17-23. PubMed ID: 18765419
[TBL] [Abstract][Full Text] [Related]
13. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene.
Liu Z; Hergenhahn M; Schmeiser HH; Wogan GN; Hong A; Hollstein M
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):2963-8. PubMed ID: 14976251
[TBL] [Abstract][Full Text] [Related]
14. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences.
Feldmeyer N; Schmeiser HH; Muehlbauer KR; Belharazem D; Knyazev Y; Nedelko T; Hollstein M
Mutat Res; 2006 Sep; 608(2):163-8. PubMed ID: 16835015
[TBL] [Abstract][Full Text] [Related]
15. Benzo[a]pyrene, aflatoxine B₁ and acetaldehyde mutational patterns in TP53 gene using a functional assay: relevance to human cancer aetiology.
Paget V; Lechevrel M; André V; Goff JL; Pottier D; Billet S; Garçon G; Shirali P; Sichel F
PLoS One; 2012; 7(2):e30921. PubMed ID: 22319594
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors.
Liu Z; Muehlbauer KR; Schmeiser HH; Hergenhahn M; Belharazem D; Hollstein MC
Cancer Res; 2005 Apr; 65(7):2583-7. PubMed ID: 15805253
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.
Nedelko T; Arlt VM; Phillips DH; Hollstein M
Int J Cancer; 2009 Feb; 124(4):987-90. PubMed ID: 19030178
[TBL] [Abstract][Full Text] [Related]
18. Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome.
Kim SI; Hollstein M; Pfeifer GP; Besaratinia A
Mol Carcinog; 2010 Dec; 49(12):999-1006. PubMed ID: 20945503
[TBL] [Abstract][Full Text] [Related]
19. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin.
Luo JL; Tong WM; Yoon JH; Hergenhahn M; Koomagi R; Yang Q; Galendo D; Pfeifer GP; Wang ZQ; Hollstein M
Cancer Res; 2001 Nov; 61(22):8158-63. PubMed ID: 11719445
[TBL] [Abstract][Full Text] [Related]
20. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72.
Reinbold M; Luo JL; Nedelko T; Jerchow B; Murphy ME; Whibley C; Wei Q; Hollstein M
Oncogene; 2008 Apr; 27(19):2788-94. PubMed ID: 17998932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
